Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.44 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.43 |
| ▸ | CD38 | P28907 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6369876 | 0.96 | HPGDS (0.45) | IRAK4CD38HPGDSMEN1KMT2A | |
| SCHEMBL6363927 | 0.95 | AURKA (0.49) | AURKAAURKBEHMT2 | |
| SCHEMBL6368598 | 0.89 | IRAK4 (0.48) | AURKAAURKBIRAK4 | |
| SCHEMBL6369862 | 0.84 | KDR (0.48) | IRAK4EHMT2MEN1KMT2A | |
| SCHEMBL8312433 | 0.81 | CD38 (0.43) | CD38 | |
| SCHEMBL6368444 | 0.80 | IRAK4 (0.45) | IRAK4CD38 | |
| SCHEMBL6368103 | 0.72 | IRAK4 (0.45) | IRAK4CD38 | |
| SCHEMBL8312573 | 0.72 | EGFR (0.52) | MEN1KMT2A | |
| SCHEMBL6363869 | 0.71 | CD38 (0.47) | CD38HPGDS | |
| SCHEMBL8312604 | 0.70 | EGFR (0.61) | IRAK4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005016925-A1 | AZAQUINAZOLINE DERIVATIVES | PFIZER LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
| US-20050038047-A1 | Azaquinazoline derivatives | EDWARDS PAUL JOHN (GB) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038047-A1 | Azaquinazoline derivatives | AZI2, P2RX5, P2RX7 | AURKA 1458/4885AURKB 1736/4885IRAK4 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.